The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program.

Shiri, Tinevimbo; Evans, Marc; Talarico, Carla A; Morgan, Angharad R; Mussad, Maaz; Buck, Philip O; McEwan, Phil; Strain, William David

Shiri, Tinevimbo; Evans, Marc; Talarico, Carla A; Morgan, Angharad R; Mussad, Maaz; Buck, Philip O; McEwan, Phil; Strain, William David.

Afiliação

Shiri T; Health Economics and Outcomes Research Ltd., Cardiff CF23 8RB, UK.
Evans M; Diabetes Resource Centre, University Hospital Llandough, Cardiff CF64 2XX, UK.
Talarico CA; Moderna, Inc., Cambridge, MA 02139, USA.
Morgan AR; Health Economics and Outcomes Research Ltd., Cardiff CF23 8RB, UK.
Mussad M; Ashfield Healthcare on Behalf of Moderna, Ashby-de-la-Zouch LE65 1HW, UK.
Buck PO; Moderna, Inc., Cambridge, MA 02139, USA.
McEwan P; Health Economics and Outcomes Research Ltd., Cardiff CF23 8RB, UK.
Strain WD; Diabetes and Vascular Research Centre, University of Exeter Medical School, Exeter EX1 2HZ, UK.

Vaccines (Basel) ; 10(2)2022 Jan 18.

Article em En | MEDLINE | ID: mdl-35214599

Palavras-chave

COVID-19; boosters; modelling; population risk

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google